cis-2,6-dimethyl-1-piperidinepropanol | 63645-16-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: cis-2,6-dimethyl-1-piperidinepropanol
• 英文别名: 3-(2r,6c-dimethyl-piperidino)-propan-1-ol；1-(propan-1'-ol)-2,6-cis-dimethyl-piperidine；3-[(2R,6S)-2,6-dimethylpiperidin-1-yl]propan-1-ol
• CAS: 63645-16-9
• 化学式: C₁₀H₂₁NO
• mdl: MFCD15731997
• 分子量: 171.283
• InChiKey: CRDBTWHALLRFOX-AOOOYVTPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-2,6-dimethyl-1-piperidinepropanol 在 氯化亚砜 作用下， 以 苯 为溶剂， 反应 2.0h， 生成 cis-1-(3-chloropropyl)-2,6-dimethylpiperidine monohydrochloride
  参考文献：
  名称：

  顺式-2,6-二甲基-α，α-二芳基-1-哌啶丁醇的合成及抗心律失常活性。

  摘要：

  评价了一系列α，α-二芳基-1-哌啶丁醇在冠状动脉结扎狗模型中的抗心律失常活性。结构-活性关系研究表明，2,6-二甲基哌啶基团产生的化合物具有最佳的抗心律失常特征。分开二芳基甲醇和氨基的亚甲基链的长度并不关键。用氢或羟基取代许多官能团对功效或持续时间影响很小，但是产生的化合物会产生严重的心动过速。用氢或吡啶基或​​环己基取代芳基之一对功效几乎没有影响，但是减少了作用时间。最终选择了化合物18（吡美诺醇）进行进一步研究，目前正在人体中进行研究。

  DOI：

  10.1021/jm00105a003
• 作为产物：
  描述：

  3-<1-(2,6-dimethyl)piperidinyl>propanenitrile 在 盐酸 、 lithium aluminium tetrahydride 、 乙醚 、 溶剂黄146 作用下， 生成 cis-2,6-dimethyl-1-piperidinepropanol
  参考文献：
  名称：

  Nikitskaja et al., Zhurnal Obshchei Khimii, 1959, vol. 29, p. 3272,3275; engl. Ausg. S. 3236, 3238

  摘要：

  DOI：

文献信息

• 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands
  申请人：Warner-Lambert Company LLC

  公开号：EP1593679A1

  公开（公告）日：2005-11-09

  The invention relates to 3- or 4-monosubstituted phenol derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  这项发明涉及3-或4-单取代酚衍生物，以及用于制备、制备中间体、含有和使用这些衍生物的过程。所述的3-或4-单取代酚衍生物是H3配体，在许多疾病、紊乱和状况中非常有用，特别是炎症性、过敏性和呼吸系统疾病、紊乱和状况。
• Cis-2,6-dimethyl-.alpha.,.alpha.-diphenyl-1-piperidinebutanol compounds
  申请人：Parke, Davis & Company

  公开号：US04031101A1

  公开（公告）日：1977-06-21

  cis-2,6-Dimethyl-.alpha.,.alpha.-diphenyl-1-piperidinebutanol; and acid-addition salts. The compounds are pharmacological agents, especially antiarrythmic agents. The compounds can be produced by reacting phenyl lithium or phenylmagnesium halide with cis-.gamma.-(2,6-dimethylpiperidino)butyrophenone or a lower alkyl ester of cis-2,6-dimethyl-1-piperidinebutyric acid; by reacting .alpha.-(3-halopropyl)-.alpha.-phenylbenzyl alcohol with cis-2,6-dimethylpiperidine, or by reacting cis-1- (3-lithiopropyl)-2,6-dimethylpiperidine with benzophenone.

  cis-2,6-二甲基-α,α-二苯基-1-哌啶丁醇；及其酸盐。这些化合物是药理学试剂，特别是抗心律失常试剂。这些化合物可以通过将苯基锂或苯基镁卤化物与顺式-γ-(2,6-二甲基哌啶基)丁酰苯酮或顺式-2,6-二甲基-1-哌啶丁酸的较低烷基酯反应而制备；通过将α-(3-卤代丙基)-α-苯基苄醇与顺式-2,6-二甲基哌啶反应，或通过将顺式-1-(3-锂代丙基)-2,6-二甲基哌啶与苯甲酮反应制备。
• Antiarrhythmic
  申请人：Parke, Davis & Company

  公开号：US04112103A1

  公开（公告）日：1978-09-05

  (+,-)-cis-.alpha.[3-(2,6-Dimethyl-1-piperidinyl)propyl]-.alpha.-phenyl-2-py ridinemethanol and acid-addition salts. The compounds are pharmacological agents, especially antiarrhythmic agents. The compounds can be produced by reacting pyridyllithium with cis-.gamma.-(2,6-dimethylpiperidino)butyrophenone, or by reacting cis-1-(3-lithiopropyl)-2,6-dimethylpiperidine with 2-benzoylpyridine. Pharmaceutical compositions comprising (+,-)-cis-.alpha.-[3-(2,6-dimethyl-1-piperidinyl)propyl]-.alpha.-phenyl-2- pyridinemethanol and acid-addition salts thereof and methods for treating cardiac arrhythmia using said pharmaceutical compositions are also disclosed.

  (+,-)-顺式-.alpha.[3-(2,6-二甲基-1-哌啶基)丙基]-.alpha.-苯基-2-吡啶甲醇及其酸盐是药理学药剂，尤其是抗心律失常药剂。该化合物可以通过将吡啶基锂与顺式-.gamma.-(2,6-二甲基哌啶基)丁酮苯反应来制备，或通过将顺式-1-(3-锂丙基)-2,6-二甲基哌啶与2-苯甲酰吡啶反应来制备。还公开了包含(+,-)-顺式-.alpha.-[3-(2,6-二甲基-1-哌啶基)丙基]-.alpha.-苯基-2-吡啶甲醇及其酸盐的制药组合物以及使用该制药组合物治疗心律失常的方法。
• Indazole compounds and methods of use thereof
  申请人：Bhagwat S. Shripad

  公开号：US20060004043A1

  公开（公告）日：2006-01-05

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防广泛的疾病和紊乱方面具有实用性，这些疾病和紊乱对激酶的抑制、调节或调控具有反应性，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病有关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛和其他疾病。因此，本发明还揭示了治疗或预防此类疾病和紊乱的方法，以及包含一种或多种吲唑化合物的药物组成物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，它们在蛋白激酶调节方面具有强效活性。因此，本发明包括口服活性分子以及可用于治疗与蛋白激酶信号转导相关的疾病或紊乱的肠外活性分子，其剂量或血清浓度较低。
• INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Bhagwat Shripad S.

  公开号：US20090099178A1

  公开（公告）日：2009-04-16

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseases or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防许多对激酶的抑制、调节或调控具有反应性的疾病和障碍方面具有用途，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病相关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还揭示了治疗或预防这些疾病和障碍的方法，以及包含一种或多种吲唑化合物的制药组合物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，这些分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和经肠道给药的活性分子，可用于治疗与蛋白激酶信号转导相关的疾病或障碍，且可用较低剂量或血清浓度。